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Abstract
Background: Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can 
be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A 
novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling 
seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies 
upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this 
study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its 
observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines 
from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. 
Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of 
various biological processes regulated by the intended target and facilitate their clinical development.
Results: Causal network modeling on transcriptomic and proteomic data identified molecular networks that are 
comprised of activated or inhibited mechanisms that could explain observed changes in the sensitive cell lines treated 
with GSK690693. Four networks common to all cell lines and xenografts tested were identified linking GSK690693 
inhibition of AKT kinase activity to decreased proliferation. These networks included increased RB1 activity, decreased 
MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity.
Conclusion: AKT is involved in regulating both cell proliferation and apoptotic pathways; however, the primary effect 
with GSK690693 appears to be anti-proliferative in the cell lines and xenografts evaluated. Furthermore, these results 
indicate that anti-proliferative responses to GSK690693 in either 2-D culture or xenograft models may share common 
mechanisms within and across sensitive cell lines.
Background
Hyperactivation of the PI3K-AKT pathway is one of the
most common molecular findings in human malignan-
cies [1,2]. Constitutive activation of this pathway can
result from several factors, including mutation and/or
amplification in certain components within this pathway,
e.g., EGFR, ERBB2, PI3K, and AKT as well as the down-
regulation or loss of negative regulators such as the serine
phosphatase, PTEN [3,4]. Increased AKT1 activity has
been observed in approximately 40% of breast and ovar-
ian cancers and >50% of prostate carcinomas. Activation
of AKT2 kinase has been observed in 30-40% of ovarian
and pancreatic cancers [3,5]. Increased AKT3 enzymatic
activity was found in estrogen receptor-deficient breast
cancer and androgen insensitive prostate cancer cell
lines, suggesting that AKT3 may contribute to the aggres-
siveness of steroid hormone-insensitive cancers [3]. AKT
signaling has been reported to promote cell survival and
proliferation across different cell types and can involve
multiple downstream mechanisms including activation of
FRAP1 (mTOR)/P70S6K1, inactivation of CDKN1B
(p27Kip), inactivation of Forkhead family transcription
factors, and increased cyclin D1 (CCND1). In breast can-
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cer cells, the anti-proliferative function of the PTEN
tumor suppressor protein has been demonstrated to
involve the inhibition of AKT-mediated cell cycle activa-
tion through both its protein and more canonical lipid
phosphatase activities and the function of the CDKN1B
cell cycle inhibitor has been shown to be directly inhib-
ited by AKT-dependent phosphorylation [6-9]. In ovarian
cancer cells, PI3K/AKT signaling has been demonstrated
to affect cell proliferation via FRAP1(mTOR)/P70S6K1-
mediated mechanisms [10,11]. Proliferation of embryonic
cardiomyocytes in cell culture has been demonstrated to
be dependent on PI3K/AKT signaling leading to inhibi-
tion of the activity of the Forkhead family transcription
factors, FOXO1A and FOXO3A [12]. In rat and mouse
cell lines, MYC-induced proliferation and transformation
was shown to require AKT-mediated phosphorylation
and inhibition of Forkhead family proteins.
AKT provides survival signals through inhibiting sev-
eral proapoptotic factors in the caspase cascade, includ-
ing BAD, (pro)caspase-9, PEA15 (PED), CDKN1A (p21/
WAF1), and MAP3K5 (ASK1) [3]. AKT also regulates
apoptosis by providing positive and negative transcrip-
tional signaling. Phosphorylation of FOXO by AKT pre-
vents its nuclear entry and thereby preventing
transcription of proapoptotic genes, including Fas ligand,
BIM, TRAIL and TRADD. In contrast [13], AKT pro-
motes nuclear translocation of NF-κB by phosphorylating
and activating IκB kinase (IKK), leading to the phospho-
rylation and proteosomal degradation of IκB (inhibitor of
NF-κB), and ultimately NF-κB nuclear localization. AKT
can also inactivate p53 by modulating subcellular local-
ization of Mdm2. Phosphorylation of Mdm2 by AKT is
necessary for localization to the nucleus, where Mdm2
can complex with p53 to promote its ubiquitin/protea-
some-mediated degradation [14].
The present study investigated mechanisms induced in
cancer cell lines in response to treatment with
GSK690693, an ATP-competitive, pan-AKT kinase inhib-
itor with potent enzyme and cellular activity being inves-
tigated in patients with solid tumor and hematological
malignancies [15]. The goal of this study was to identify
mechanisms that were common to a set of cell lines sensi-
tive to GSK690693 and to evaluate those mechanisms for
their potential effects on cell survival and proliferation.
Candidate mechanisms were identified via analysis of
gene expression profiling data and phosphoproteomic
data using a causal network modeling methodology
called "Reverse Causal Analysis" (RCA) [16,17]. RCA
enables the mechanistic interpretation of large datasets
using a large network model of biological cause and effect
relationships. In RCA, the causal network upstream from
entities observed to change in the experiment (such as
RNA abundances measured by microarray) is automati-
cally evaluated to identify and rank many thousands of
subnetworks that express potential mechanistic explana-
tions for the observed changes. Biologists using RCA
methodology can then construct a Causal Network
Model (CNM) where multiple mechanism networks and
their supporting evidence are merged to form a unified
causal network consistent with the input datasets. The
CNM represents the set of hypotheses explaining the
observed changes. The CNM in the present study is fur-
ther constrained to contain only those subnetworks that
are supported by the observed changes in all sensitive cell
l i n e s :  i t  r e p r e s e n t s  t h e  c o m m o n  s e t  o f  h y p o t h e s e s  f o r
mechanisms of sensitivity to GSK690693.
Results
Inhibition of cellular AKT activity by GSK690693
GSK690693 inhibits proliferation of certain tumor cell
lines in vitro and attenuates the growth of human tumor
xenografts in mice [15]. To investigate the molecular cas-
cade leading to the inhibition of cell proliferation by
GSK690693, various tumor cell lines growing in cell cul-
ture or as xenografts in mice were treated with vehicle or
GSK690693. Cell lines used in this study were either clas-
sified as sensitive to GSK690693 (IC50 < 200 nM): T47D,
BT474, and LNCaP or less sensitive (IC50 > 800 nM):
MDA-MB-453, MDA-MB-468, and SKOV3 [15]. Daily
treatment of mice with GSK690693 inhibited growth of
BT474, LNCaP, and SKOV3 tumor xenografts [15].
Microarray analysis was used to generate RNA profiles
for the cell culture experiments (BT474, T47D, MDA-
MB-468, MDA-MB-453, LNCaP, and SKOV-3) as well as
for the xenograft experiments (BT474, LNCaP, and
SKOV-3). Changes in the phosphorylation of various pro-
teins following GSK690693 treatment were analyzed for
the BT474, T47D, MDA-MB-468, and MDA-MB-453
breast cancer cells in cell culture using reverse phase pro-
tein array (RPPA). Treatment with GSK690693 resulted
in a decrease in the abundance of phosphorylated AKT
substrates, pGSK3a/b (S9/21), pFKHR/FKHRL1 (T24/
32), pmTOR (S2448), pBAD (S112), and pPRAS40 (T246)
in BT474, T47D, MDA-MB-468, and MDA-MB-453 cells
(Figure 1), providing direct evidence for the inhibition of
AKT kinase activity by GSK690693. Causal network
modeling was used to identify chains of causation linking
the upstream perturbation to downstream hypotheses
identified by RCA incorporating phosphoproteomic and
transcriptomic changes as evidence. For example the
observed decrease in GSK3B and FRAP1 phosphoryla-
tions support decreased MYC activity in response to
AKT inhibition.
AKT inhibition can increase transcriptional activity of 
FOXO1A and FOXO3A
AKT directly phosphorylates FOXO1A and FOXO3A at
T24/S256 and T32/S253, respectively, excluding the pro-Kumar et al. BMC Genomics 2010, 11:419
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teins from the nucleus and effectively inhibiting their
transcriptional activities [18,19]. Thus, inhibition of AKT
by GSK690693 can increase FOXO transcriptional activ-
ity, by decreasing its phosphorylation. Decreased phos-
phorylation of FOXO1A/FOXO3A was observed in the
BT474, T47D, MDA-MB-453, and MDA-MB-468 cell
culture experiments after treatment with GSK6906936
(Figure 1). RCA of RNA expression changes supports
increased transcriptional activity of FOXO3A in all three
xenografts and FOXO1A in two of the three xenografts
(BT474 and LNCaP). RCA of RNA expression changes
supports the increased transcriptional activity of both
FOXO1A and FOXO3A in the BT474, T47D, SKOV-3,
and LNCaP cells treated in culture (Figure 2). There is
approximately a 50% overlap between the RNA expres-
sion changes explained by the two FOXO family mem-
bers, and collectively they explain 31, 35, and 45 RNA
expression changes observed after three days of drug
treatment in BT474, SKOV-3, and LNCaP xenografts,
respectively (Additional file 1 Table S1 contains a sum-
mary table of RNA expression changes in these studies).
Increased transcriptional activity of FOXO1A and
FOXO3A also explains 87, 59, 89, and 107 transcriptional
changes in BT474, T47D, SKOV-3, and LNCaP cultured
cells, respectively (BT474 and T47D cells 24/48 hours
pooled, SKOV-3 and LNCaP cells at 24 hours) (Figure 2,
Additional file 2 Table S2). Increased transcriptional
activity of FO XO1A and FO XO3A is not supported by
Figure 1 Treatment with GSK690693 leads to inhibited phosphorylation of kinase targets of AKT. Inhibition of AKT kinase activity is evidenced 
by decreased phosphorylation of kinase targets of the protein, including PRAS40 (AKT1S1), mTOR (FRAP1), FKHR/FKHRL1 (FOXO1A/FOXO3A), BAD and 
GSK3a/b in BT474, MDA-MB-453, MDA-MB-468, and T47D breast cancer cell lines, mean +/- S.D. Bar graphs: blue: control, red: treated with GSK690693; 
y-axis: relative intensity units.
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RCA in the two cell lines less sensitive to GSK690693
MDA-MB-453 and MDA-MB-468 cells (Data not
shown). Increased nuclear translocation of a FOXO3--
green florescent protein hybrid in response to
GSK690693 treatment in U2OS cells has been shown pre-
viously, in confirmation of these results [15].
Decreased MYC transcriptional activity
RCA identifies RNA expression changes that strongly
support decreased transcriptional activity of MYC in all
three xenografts as well as in four sensitive tumor cell
lines in culture. Inhibition of AKT can lead to decreased
transcriptional activity of MYC through multiple mecha-
nisms. Decreased MYC activity can correctly explain 31,
61, and 54 RNA expression changes in the BT474, SKOV-
3, and LNCaP xenografts, respectively (Figure 3, Addi-
tional file 3 Table S3). Decreased MYC activity is also
supported by RNA expression changes in BT474 and
T47D (24/48 hours pooled),,SKOV-3, and LNCaP cul-
tured cells at 24 hours (Figure 3, Additional file 3 Table
S3). Decreased transcriptional activity of MYC is not sup-
ported by RCA in the MDA-MB-453 and MDA-MB-468
cells (Data not shown).
Although MYC RNA levels are not observed to be sig-
nificantly changed in any cell line at any time point fol-
lowing drug treatment (Additional file 4 Figure S1),
multiple mechanisms can link AKT inhibition to
decreased MYC protein abundance and transcriptional
activity. In the SKOV-3 cell culture experiment, evidence
supporting decreased MYC activity is observed as early
as two hours after treatment (Additional file 5 Table S4)
and in the LNCaP cell culture experiment at eight hours
after treatment, consistent with fast, post-translational
control of MYC. AKT directly phosphorylates GSK3β
leading to inhibition of its kinase activity, and decreased
GSK3β phosphorylation is observed in response to AKT
inhibition by GSK690693 treatment (Figure 1). Active
GSK3β phosphorylates MYC at residue T58, thereby tar-
geting MYC for degradation by FBXW7 [20]. AKT phos-
phorylates FRAP1 (mTOR) at S2448 increasing FRAP1
kinase activity, and decreased FRAP1 S2448 phosphory-
lation was observed in the breast cancer cell lines (Figure
1) [21]. Additionally, AKT directly phosphorylates
AKT1S1 (PRAS40), and this phosphorylation acts to
block the inhibitory binding of AKT1S1 to FRAP1 [22].
Decreased phosphorylation of AKT1S1 at T246 was
observed in all four breast cancer cell lines in response to
GSK690693 treatment (Figure 1). Increased FRAP1 activ-
ity can lead to increased activity of EIF4E, a translation
initiation factor that directly increases MYC translation,
decreasing FRAP1 activity that could result in decreased
protein abundance of MYC [23].
FOXO3A/FOXO1A transcriptional activities can
inhibit the induction of multiple MYC target genes [24]
Figure 2 Changes in RNA expression levels of genes controlled by FOXO3A support transcriptional activation of FOXO. Upper Panels: Genes 
that are consistent with increased transcriptional activity FOXO3A are green, those inconsistent are red. Lower panels: Genes that are consistent with 
increased transcriptional activity FOXO3A are red, those inconsistent are green. Both panels: Genes that are not considered to be changed due to a 
non-significant fold change or p-value are white. Genes which are inconsistent with the predicted activity are represented in Additional file 1 Table 
S1 with an "X".
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and can upregulate the expression of specific cell cycle-
inhibitory genes that are also downregulated by MYC
activity, such as HBP1,  CCNG2, and CDKN1B. RNA
expression of these three genes was increased in multiple
cell culture and xenograft experiments, consistent with
increased FOXO1A/FOXO3A and decreased MYC tran-
scriptional activity (Additional file 6 Figure S2).
Proteins of the MAD family are another potential regu-
lator of MYC activity [25]. Transcript levels of MXI1, a
MAD family member that inhibits MYC activity, were
observed to be increased in response to GSK690693
treatment in SKOV-3, BT474, and LNCAP cell culture
experiments and in BT474 xenografts (Additional file 7
F i g u r e  S 3 ) .  T h i s  i s  c o n s i s t e n t  w i t h  r e c e n t  f i n d i n g s  i n
DLD-1 colon carcinoma cells in which AKT2 silencing
resulted in increased FOXO3A activity leading to
increased MXI1 RNA expression [26].
Decreased TFRC activity
RCA identified RNA expression changes that support
decreased TFRC activity in SKOV-3 and LNCaP xeno-
grafts and in T47D, SKOV-3, and LNCaP cultured cells
(Figure 3, Additional file 8 Table S5). Increased AKT
activity can increase TFRC cell surface expression, lead-
ing to increased TFRC activation [27]. TFRC has recently
been reported to be a direct transcriptional target of
MY C, and TFRC was shown to be required for MY C-
mediated cell proliferation [28], providing a direct mech-
anism by which AKT can mediate TFRC cell surface
expression. TFRC RNA levels were decreased in response
to treatment in the SKOV-3 xenograft, and in BT474,
SKOV-3, and LNCaP cell culture experiments (Addi-
tional file 9 Figure S4). Decreased TFRC activity explains
43 and 34 RNA expression changes in the SKOV-3 and
LNCaP three day xenografts, respectively. Decreased
TFRC activity also explains 66, 90, and 125 RNA expres-
sion changes in T47D, SKOV-3, and LNCaP cultured cells
(Figure 3, Additional file 8 Table S5). Decreased TFRC
activity is not supported by RCA in the MDA-MB-453
and MDA-MB-468 cells (Data not shown).
RB1-mediated G1 cell cycle arrest
RCA identifies RNA expression changes that support
increased cell cycle arrest in all three xenografts and RNA
expression and phosphoprotein changes that support
increased cell cycle arrest in BT474, T47D, SKOV-3, and
LNCaP cultured cells (Figure 4). RNA expression changes
strongly support an increase in cell cycle arrest based on
evidence for increased activity of cell cycle suppressors
CDKN1A, RB1, and E2F4, and decreased activity of cell
cycle activators E2F1, E2F2, and E2F3 (Figure 4).
RB1 is a cell cycle regulatory protein that can inhibit
the G1/S transition [29] and the M/G1 transition [30].
The activation of RB1-mediated transcription and its
effects on this regulatory network by GSK690693 can col-
lectively explain 13, 36, and 33 RNA expression changes
in the BT474, SKOV-3, and LNCaP xenografts, respec-
tively, at three days. The activation of RB1 also explains
81, 103, 139, and 154 RNA expression changes in the
BT474, T47D, SKOV-3, and LNCaP cell cultures (Figure
4, Additional file 10 Table S6). The activation of RB1 is
not supported in the MDA-MB-453 and MDA-MB-468
cells (Data not shown).
AKT inhibition can lead to RB1 activation and cell cycle
arrest through multiple independent mechanisms includ-
ing activation of the cell cycle inhibitor CDKN1A [31-33].
AKT can directly phosphorylate CDKN1A inhibiting the
activity of this protein by secluding it in the cytoplasm
[34]. Increased CDKN1A activity due to AKT inhibition
is strongly supported by 16, 36, and 30 RNA expression
changes in the BT474, SKOV-3, and LNCaP xenograft
Figure 3 Inhibition of MYC and consequent inhibition of TFRC. A) 
Upper Panels: Genes that are consistent with decreased transcriptional 
activity MYC are green, those inconsistent are red. Lower panels: Genes 
that are consistent with decreased transcriptional activity MYC are red, 
those inconsistent are green. B) Upper Panels: Genes that are consistent 
with decreased TFRC activity are green, those inconsistent are red. 
Lower panels: Genes that are consistent with decreased TFRC activity 
are red, those inconsistent are green. All panels: Genes that are not con-
sidered to be changed due to a non-significant fold change or p-value 
are white. Genes that are inconsistent with the predicted activity are 
represented in Additional file 2 Table S2 and Additional file 8 Table S5 
with an "X".
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three day experiments, respectively. Increased CDKN1A
activity also explains 58, 84, 114, and 121 RNA expression
changes in the BT474, T47D, SKOV-3, and LNCaP cell
culture experiments, but is not supported in the MDA-
MB-453 and MDA-MB-468 cell culture experiments (Fig-
ure 4, Additional file 11 Table S7, Data not shown).
The E2F family of transcription factors regulates cell
cycle progression, with the activities of E2F1, E2F2, and
E2F3 promoting cell cycle progression and the activity of
E2F4 inhibiting cell cycle progression [35]. Decreased
E2F1 transcriptional activity is supported by RNA
expression changes in all three xenograft experiments
(10, 17, and 11 RNA expression changes in BT474,
SKOV-3, and LNCaP, respectively) as well as in cultured
cells (49, 51, 70, and 76 in BT474, T47D, SKOV-3, and
LNCaP, respectively) (Figure 4, Additional file 12 Table
S8). Decreased transcriptional activity of E2F2 and E2F3,
and increased transcriptional activity of E2F4 are sup-
ported by RNA expression changes in all three xenografts
and BT474, T47D, SKOV-3, and LNCaP cells (Data not
shown). Increased transcriptional activity of E2F4 and
decreased transcriptional activities of E2F1, E2F2, and
E2F3 are not supported by RCA in the MDA-MB-453 and
MDA-MB-468 cells (Data not shown).
Distinct sets of gene expression changes support the same 
hypotheses, and the hypotheses form a Causal Network 
Model providing a mechanism that links AKT inhibition 
with reduced proliferation
As represented in Figure 5, three very distinct sets of
RNA expression changes were identified in response to
GSK690693 treatment in three xenograft experiments.
Seventeen RNA expression changes were common to all
three xenograft experiments. However, the hypotheses of
increased FOXO activity, increased cell cycle arrest,
decreased MYC transcriptional activity, and decreased
TFRC activity correctly explain 31%, 26%, and 31% of the
RNA expression changes in each of the three xenograft
experiments (BT474, SKOV-3, and LNCaP), respectively.
Similar explanatory power of these hypotheses is seen in
the cell culture experiments, in which 33%, 50%, 45%, and
32% of RNA expression changes were correctly explained
in BT474, T47D, SKOV3, and LNCaP cells, respectively.
In contrast to the small overlap in RNA expression
changes, the four mechanisms supporting GSK690693
driven anti-proliferative effects identified by RCA form a
Causal Network Model that can correctly explain a large
portion of the RNA expression changes identified in each
xenograft and cell culture experiment (Figure 6). The
power of causal analysis is exemplified by the expression
changes related to two cell cycle marker genes, PCNA
Figure 4 Regulation of cell cycle controllers is evidenced by 
changes in RNA expression levels. A) Upper Panels: Genes that are 
consistent with decreased transcriptional activity of E2f1are green, 
those inconsistent are red. Lower panels: Genes that are consistent with 
decreased transcriptional activity of E2f1 are red, those inconsistent are 
green. B) Upper Panels: Genes that are consistent with increased activ-
ity of CDKN1A are green, those inconsistent are red. Lower panels: 
Genes that are consistent with increased activity of CDKN1A are red, 
those inconsistent are green. C) Upper Panels: Genes that are consistent 
with increased transcriptional activity of RB1 are green, those inconsis-
tent are red. Lower panels: Genes that are consistent with increased 
transcriptional activity of RB1 are red, those inconsistent are green. All 
panels: Genes that are not considered to be changed due to a non-sig-
nificant fold change or p-value are white. Genes that are inconsistent 
with the predicted activity are represented in Additional files 10, 11 
and 12 Tables S6-S8 with an "X".
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Figure 5 Different gene changes support the same processes in 
cell culture and xenograft experiments. The transcriptomic re-
sponse to GSK690693 treatment is markedly different in three xeno-
graft models derived from distinct tissues, with only 17 common 
expression changes (<1% of total). In contrast, a common set of pro-
posed sensitivity mechanisms can explain roughly one-third of the ex-
pression changes in each cell line.
SKOV3
1004
LNCaP
763
236
902
626
17
63 57
29
BT474 SKOV3
LNCaP
Causal
Analysis
correctly 
explained
32%
not 
explained
68%
correctly 
explained
32%
not 
explained
68%
correctly 
explained
not explained 
71%
correctly 
explained
29%
not explained 
71%
correctly 
explained
34%
not explained
66%
correctly 
explained
34%
not explained
66%
BT474
345
Proposed
sensitivity
mechanismsKumar et al. BMC Genomics 2010, 11:419
http://www.biomedcentral.com/1471-2164/11/419
Page 7 of 12
Figure 6 Summary of processes which are affected by GSK690693 treatment. Activating causal relationship; Inhibiting causal relationship. Note 
that this is a summary representation: in the actual Causal Network Model protein activities are differentiated from protein abundances and protein 
modifiers such as phosphorylations.
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and MKI67. Although the increased cell cycle arrest
hypothesis was well supported in all experiments,
changes in these two genes failed to meet significance cri-
teria in one or more of the xenograft experiments. Each
of the four mechanisms is well supported by RNA expres-
sion changes from each xenograft and cell culture experi-
ment; however the specific expression patterns
supporting the mechanisms are minimally overlapping.
Discussion
The AKT family of kinases has been well characterized as
a mediator of cell proliferation and survival, and these
functionalities highlight the role of these kinases in tumor
progression [2,3]. In this study, we characterized molecu-
lar signaling networks that are activated or inhibited by
AKT inhibition by GSK690693 treatment using gene
microarray data from multiple cell lines and xenograft
models and phosphoproteomics analysis from multiple
cell lines.
The focus of this analysis was to identify common
mechanisms of action for GSK690693 treatment in
breast, prostate, and ovarian cancer cell lines in both cell
culture and xenograft models. RCA enabled the analysis
of large, transcriptomic data sets in combination with a
more targeted phosphoproteomics data set to identify
mechanisms of action for this AKT inhibitor that were
supported by specific RNA expression and phosphopro-
tein changes following GSK690693 treatment.
Treatment with GSK690693 inhibited the kinase activ-
ity of AKT, and led to alterations in multiple downstream
signaling pathways (Figure 1). The four hypotheses iden-
tified by RCA form a Causal Network Model in which
inhibition of AKT leads to cell cycle arrest and inhibition
of proliferation (Figure 6). The increased transcriptional
activity of FOXO1A and FOXO3A can directly increase
the expression of cell cycle inhibitors, such as HBP1,
CCNG2, and CDKN1B, and these genes were upregu-
lated in the majority of the sensitive cell culture and
xenograft experiments (Figure 2). The expression of these
three genes is repressed through the activity of MYC. The
pro-proliferative effect of MYC activation is well estab-
lished [36], and repression of the transcriptional activity
of this protein, which was supported by RCA, would lead
to decreased cell proliferation (Figure 3). TFRC is a MYC-
regulated gene that was observed to be decreased in
response to GSK690693 treatment in some of the cell
lines and xenografts. Furthermore, decreased protein
abundance of TFRC was supported by RCA, and TFRC
cell surface expression has been shown to be greater in
cancer cells than in normal cells [37] and a positive corre-
lation has been reported between the number of cell sur-
face transferrin receptors and the rate of cell proliferation
[38-40]. Inhibition of TFRC decreases cell proliferation
and results in G1 arrest, consistent with the tumor
growth inhibition observed in the sensitive cell culture
and xenograft experiments (Figure 3). AKT inhibition can
also directly stimulate cell cycle arrest through attenua-
tion of the direct inhibitory AKT-mediated phosphoryla-
tion of the cell cycle inhibitors CDKN1A and CDKN1B,
as well as through modulation of the activity of the signal-
ing intermediate GSK3β (Figure 4). In combination, these
four hypotheses describe a mechanism for inhibition of
proliferation due to AKT inhibition, primarily through
cell cycle arrest and identified inhibition of proliferation,
as opposed to the more canonical survival role attributed
to AKT signaling, as the primary process responsible
(Figure 6).
AKT activation results in both anti-apoptotic and pro-
proliferative signals, although the evidence for induction
of apoptosis was generally lacking or weak in our study
with the AKT kinase inhibitor, suggesting that AKT plays
a more critical role in regulating cell proliferation in epi-
thelial cancer cells. This is in contrast to findings in lym-
phoblastic leukemia cells lines treated with GSK690693
in which caspase 3/7 induction and concomitant
increased sub-2N populations were observed in addition
to decreased proliferation [41]. Treatment with
GSK690693 resulted in increased FOXO1A and FOXO3A
transcriptional activity, although the transcript levels of
pro-apoptotic genes (e.g., BCL2L11 and TNFSF10) were
not consistently upregulated in most of the cell culture
and xenograft models. Similarly, causal analysis did not
identify change in the NF-κB transcriptional activity in
any of the model systems upon treatment with
GSK690693. Further, phosphorylation of BAD was
decreased in cells treated with GSK690693 (Figure 1),
suggesting regulation of apoptotic pathways. Although
there was some evidence of apoptosis in LNCaP and
BT474 cells at 24-48 h (data not shown), the other cell
lines did not show evidence of this process. Taken
together, our data suggest that inhibition of AKT kinases
can regulate both cell proliferation and apoptotic path-
ways. This is consistent with previous findings that
GSK690693 treatment inhibited tumor formation in a
mouse model that spontaneously develops lymphomas
through both induction of apoptosis as well as inhibition
of proliferation [42]. However, the primary mechanism of
action of GSK690693 observed in this study appears to be
anti-proliferative in the cell lines and xenografts evalu-
ated. Collectively these data indicate that the balance of
the role of AKT signaling in either cell survival or prolif-
eration is likely to be dependent on tumor type.
In this study, independent identification of hypotheses
supported by a preponderance of evidence in each cell
culture and xenograft experimental model enabled the
comparison of the drug mechanism of action in each dis-
tinct experimental model at the hypothesis level. Further,
as evidenced in this study, while treatment with the sameKumar et al. BMC Genomics 2010, 11:419
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compound can lead to large and mostly non-overlapping
changes in cell lines and xenografts from various histo-
logical origins, underlying mechanisms of action are con-
served (Figure 5). Interestingly, as demonstrated in Figure
5, the Causal Network Model of common mechanisms of
sensitivity to GSK690693 derived by RCA only accounted
for between 29-34% of the RNA-based xenograft changes
(Figure 5) (similar coverage was also achieved by RCA on
2-D culture data (not shown)). This suggests that there
are clearly additional mechanisms of response to
GSK690693 that are not accounted for by the current
causal model. There are several factors that may account
for this observation. First, the goal of the analysis was to
identify conserved mechanisms of response in sensitive
cell lines, thus excluding those mechanisms supported by
the data that were unique to specific cell lines. Addition-
ally, as the RCA methodology is based on the causal
knowledge modeled for each gene expression change that
is linked to underlying literature knowledge of each tran-
script/protein, therefore expression changes where such
information is sparse are less likely to contribute signifi-
cantly to the causal model.
Conclusions
W e  h a v e  d e m o n s t r a t e d  t h e  m e c h a n i s m  o f  a c t i o n  o f  a
novel AKT kinase inhibitor, GSK690693, using a Causal
Network Model, that allows a diverse data set to be
explained by common hypotheses. Inhibition of AKT
kinases in cell culture and tumor xenografts results in cell
cycle inhibition by altering various cellular mechanisms,
which are interrelated. These mechanisms include
increasing FOXO transcriptional activity, inhibition of
MYC transcriptional activity, decreased TFRC activity,
and induction of RB1-mediated cell cycle arrest. Our
findings demonstrate one of the main tenets of systems
biology, that the networks that regulate cellular processes
are often conserved across various tumor and tissue
types, even when the transcriptional response of these
tissues is markedly different.
Methods
GSK690693 preparation
GSK690693 was synthesized at GlaxoSmithKline. For all
in vitro studies, GSK690693 was dissolved in DMSO at a
concentration of 10 mM prior to use and subsequently
diluted in aqueous medium. For the tumor xenograft
studies, GSK690693 was formulated in either 4% DMSO/
40% hydroxypropyl-β-cyclodextrin in water, pH6.0.
Animals
F e m a l e  C D 1  S w i s s  N u d e  m i c e  w e r e  o b t a i n e d  f r o m
Taconic (Hudson, NY) and C.B-17 SCID mice were
obtained from Charles River (Wilmington, MA). All ani-
mal studies were performed in compliance with federal
requirements, GlaxoSmithKline policy on the Care and
Use of Animals, and with related codes of practice.
Sample preparation for RNA and Phosphoprotein analysis
Human tumor cell lines BT474, T47D, MDA-MB-468,
MDA-MB-453, LNCaP, and SKOV-3 were treated with 1
μM GSK690693 for 2, 8, 24, and 48 h (N = 3 or 4 repli-
cates/treatment group) and lysates were prepared in Tri-
zol for RNA expression analysis. Phosphorylation of
various AKT substrates was analyzed in breast carcinoma
cell lines treated for 10 min, 30 min, 2 h, or 24 h of treat-
ment (N = 2 replicate/time point) using reverse phase
protein microarray.
Tumor xenografts were initiated by injection of tumor
cell suspension (LNCaP) or tumor fragments (BT474,
SKOV-3) subcutaneously in 8-12 week old CD1 Swiss
N u d e  m i c e  ( L N C a P ,  S K O V - 3 )  o r  S C I D  m i c e  ( B T 4 7 4 ) .
When tumors reached a volume of 100-200 mm3, mice
were randomized and divided into groups of 8-12 mice/
group. GSK690693 was administered once daily at 30 mg/
kg by IP administration. Tumor tissues were harvested
after dosing for 3, 7, or 21 days (n = 3 mice/group/time
point) and homogenized in Trizol. Total RNA was iso-
lated from each Trizol lysate using RNeasy reagents (Qia-
gen, Valencia, CA) and was quantified by spectroscopy
and quality assessed using an Agilent Bioanalyser. Five
micrograms of high quality total RNA was used to gener-
ate amplified cRNA probe material using the Eberwine
protocol (Van Gelder et al., 1990) and hybridized over-
night using U133 Plus 2.0 GeneChips (Affymetrix, Santa
Clara, CA). GeneChip washing and scanning were per-
formed according to manufacturer's instructions.
Reverse-phase Protein Array
Protein arrays were constructed as described previously
[15]. Briefly, serially diluted protein lysates were printed
in duplicate onto nitrocellulose-coated glass slides. The
lysate arrays were incubated for at least 5 hours in block-
i n g  s o l u t i o n  [ 1  g  I - b l o c k  ( T r o p i x ,  B e d f o r d ,  M A ) ,  0 . 1 %
Tween-20 in 500 mL PBS] at room temperature with con-
stant rocking. Blocked arrays were stained with pGSK3a/
b (S9), pFOXO (T24/32), pFOXO (S256), pmTOR
(S2448), pBAD (S112), and pPRAS40 (T246) antibody on
an automated slide stainer. All antibodies were obtained
from Cell Signaling Technology (Beverly, MA), except
phospho-PRAS40 antibody which was purchased from
Biosource (Carlsbad, CA). Stained slides were scanned
individually on a UMAX PowerLook III scanner (UMAX,
Dallas, TX, USA) at 600 dpi and saved as TIF files in Pho-
toshop 6.0 (Adobe, San Jose, CA, USA). The TIF images
for antibody-stained slides and Sypro-stained slide
images were analyzed with MicroVigene image analysis
software, version 2.200 (Vigenetech, North Billerica, MA)
and Microsoft Excel 2000 software. Images wereKumar et al. BMC Genomics 2010, 11:419
http://www.biomedcentral.com/1471-2164/11/419
Page 10 of 12
imported into Microvigene, which performed spot find-
ing, local background subtraction, replicate averaging,
and total protein normalization, producing a single value
for each sample at each endpoint.
Data Analysis
Microarray data was analyzed using the R-based Biocon-
ductor suite of analytical tools to determine genes that
changed state across a variety of comparisons. RMA anal-
ysis was applied to generate expression values from the
Affymetrix CEL files. Principle component analysis was
applied to the expression values for each group of
microarrays to determine if any samples differed dramati-
cally from the set of similar microarrays. Significant gene
expression changes for all but the LNCaP 3 day xenograft
comparison were generated based on ANOVA adjusted
p-values of 0.05 corrected for multiple testing effects
using Benjamini-Hochberg FDR and fold changes of at
least 1.3. As the purpose of this analysis was to determine
common mechanisms of action across diverse cell lines
and xenografts, the choice of a conservative minimum
fold change selection of 1.3 was appropriate in that it
ensured that hypotheses were supported by clear experi-
mental evidence. Due to the large number of fold changes
in the LNCaP 3 day xenografts an unadjusted p-value of
0.01 was used without a fold change criteria.
Phosphoproteomic values were determined using
reverse phase proteomic analysis. The resulting values
were analyzed using the ratios of the treated and vehicle
cell lines at 10 and 30 minutes, 2 and 24 hours. The pres-
ence of a significant change was determined by a 20 per-
c e n t  d e c r e a s e  o r  a  5 0  p e r c e n t  i n c r e a s e  i n  t h e  t r e a t e d
compared to the vehicle samples. These cutoff thresholds
were determined empirically to enable changes to con-
tribute to the analysis across cell lines.
Causal Reasoning Methodology
In this study, the activation or inhibition of specific bio-
logical signaling networks were identified as explanations
for statistically significant RNA gene expression changes
observed in response to treatment with GSK690693 in
multiple cell lines. These networks represent mechanistic
hypotheses for molecular effects of GSK690693 and
together they comprise a network called a Causal Net-
work Model (CNM) that links GSK690693 treatment to a
l a r g e  f r a c t i o n  o f  t h e  o b s e rv e d  d a t a  i n  m u l t i p l e  e x pe r i -
ments via common mechanisms. These networks were
identified in a two-stage process: (1) Reverse Causal
Analysis, an automated analysis of the experimental data
using a large, literature-derived network of cause-and-
effect relationships, the Genstruct Human Knowledge
Assembly Model, and (2) a software-assisted methodol-
ogy enabling scientists to vet the results of the automated
analysis and to produce the explanatory networks. Note
that this process is a means to explain observed data in
the context of existing knowledge, distinct from
approaches that attempt to infer novel causal relation-
ships from observed data.
The Human Knowledge Assembly Model (KAM) is a
set of human-specific causal assertions that has been aug-
mented with orthologous causal assertions derived from
either rat or mouse sources. Each causal assertion is the
result of manual curation of the scientific literature and is
supported by one or more specific scientific citations. An
example causal assertion would be: increased transcrip-
tional activity of NF-KB complex causing an increase in
the gene expression of the insulin receptor substrate 1
(Irs1) (Ruan et al., 2002).
Reverse Causal Analysis (RCA) of experimental data
evaluates each node in the KAM as a hypothesis, a poten-
tial cause for observed differential measurements in an
experiment. By computing statistical figures of merit for
each hypothesis, RCA enables each hypothesis to be
ranked by multiple criteria (see below) and prioritized for
inclusion in larger explanatory networks. RCA starts with
the quantification of differential measurements as "state
c h a n g e s " ,  r e d u c i n g  v a l u e s  t o  b e  o n e  o f  " i n c r e a s e " ,
"decrease" or "no change". While these differences are
referred to as "changes" , in fact they can be any differ-
ences in state between two biological systems, such as
differential protein expression between drug-sensitive
and insensitive cell lines, or differential RNA expression
between tissues of knockout and wild-type animals. State
changes are then assigned to nodes in the KAM that rep-
resent entities corresponding to the measurements. In
the case of transcriptomic data, state changes are mapped
to nodes representing RNA abundances. Finally, every
node in the KAM is evaluated as a hypothesis, where a
hypothesis is a potential explanation for some subset of
the state changes. A node evaluated as a hypothesis is the
"root" of the hypothesis and the hypothesis is composed
by assuming that the root node has a value of "increased"
and then searching a defined number of steps in the net-
work of the KAM for all causal paths leading from the
root node to a mapped state change. Each state change
node found by this search is a "prediction" of the hypoth-
e s i s  a n d  i s  a s s i g n e d  a  p o l a r i t y  o f  e i t h e r  " i n c r e a s e " ,
"decrease", or "ambiguous". The polarity assignment is
based on the sequence of inverting and non-inverting
causal relationships traversed in each path from the root
node to the state change node. If the state change node
can be reached by paths making contradictory polarity
assignments, it is assigned a polarity of "ambiguous". The
set of predictions for each hypothesis is then evaluated
with respect to the mapped state changes by calculating
two figures of merit: Richness and Concordance p-values.
Richness is a measure of the relevance of a hypothesis to
the changes observed in the experiment, while Concor-Kumar et al. BMC Genomics 2010, 11:419
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dance is a measure of the accuracy of the predictions of a
hypothesis. Both Richness and Concordance cast the pre-
dictions and the measurement data into canonical forms
for probability analysis. Richness is a measure of the over-
representation of observed state changes in the set of
genes for which a hypothesis makes predictions. For
example, observed state changes are overrepresented if
only 1% of all genes measured show significant change
but 10% of the genes for which a hypothesis makes pre-
dictions show significant change. Richness is the signifi-
cance of the overrepresentation, calculated as a p-value
based on the hypergeometric distribution, i.e. sampling
without replacement. It is the likelihood of having Q state
changes both predicted to change and observed to
change, given N total measurements, M total significant
changes and P predictions. Note that Richness does not
depend on whether the observed direction of any change
agrees with the predicted direction; hence ambiguous
predictions may be included in the calculation. Concor-
dance is a measure of the correctness of the predictions of
the hypothesis, whether observed changes agree with
unambiguous predictions. The direction of the hypothe-
sis root is taken to be the direction that results in the
higher number of successful predictions. The stronger
the biases of the supporting evidence in favor of a
hypothesis root direction, the more concordant the
hypothesis. The significance of this bias is calculated as a
p-value based on the binomial distribution. For hypothe-
sis A, if K is the number of state changes supporting
increased A and J is the number of state changes support-
ing decreased A, then Concordance of A is the probabil-
i t y  o f  m a k i n g  H  o r  m o r e  ( H  =  m a x  ( J , K ) )  c o r r e c t
predictions out of (J + K) total predicted and observed
changes given that the null probability of the prediction
(increase or decrease) matches the observed change
(increase or decrease) is 0.5. Richness and Concordance
are metrics of the significance of a hypothesis: whether
the hypothesis can explain more of the observed changes
than would be expected by chance and whether its pre-
dictions are more consistent than would be expected by
chance.
In the second stage of the analysis, the hypotheses pro-
duced for each dataset were filtered for significance and
presented in an analysis interface that facilitated the sort-
ing of hypotheses by multiple criteria, comparison of
hypotheses between experiments, and the investigation
of the literature citations supporting each hypothesis. A
hypothesis was considered to be statistically (although
not necessarily biologically) significant if it met richness
and concordance probability cutoffs of 0.05, and margin-
ally significant if it met richness and concordance proba-
bility cutoffs of 0.1. Scientists using this analysis interface
selected hypotheses for inclusion in the explanatory net-
works and eventually the CNM based on criteria includ-
ing (1) whether the nodes in the hypothesis were causally
linked to phenotypes and processes observed in the
study, (2) whether the hypothesis node was causally
downstream from GSK690693, (3) whether the root node
was causally connected to other hypothesis root nodes,
and (4) whether the root node itself was an increased or
decreased state change. The four mechanisms presented
in this report are the networks common to the Causal
Network models constructed for each treatment of sensi-
tive cell lines in cell culture and xenografts. A summary
overview of the Causal Reasoning methodology is shown
in Additional file 13 Figure S5. References for all data in
the additional files can be found in Additional file 14
Table S9.
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